pharmaceuticals
26 stories related to this topic, newest first.
New York PostTakeda to Pay $13.6 Million to Resolve False Claims Allegations Over Trintellix Kickbacks
Takeda Pharmaceuticals U.S.A. Inc. agreed to pay $13,670,921 to settle allegations that it paid kickbacks to physicians to induce prescriptions of its antidepressant Trintellix reimbursed by Medicare and other federal health care programs. The settlement requires the company to i…
insidermonkey.comCorbus Pharmaceuticals Reports Director Departure and Shareholder Votes
Corbus Pharmaceuticals Holdings Inc. disclosed the departure of a board member and the results of its annual shareholder meeting in an 8-K filing. The changes trigger standard SEC follow-on disclosures and shift board composition effective immediately.
finance.yahoo.comAquestive Therapeutics Enters New Credit Agreement and Terminates Prior Facility
Aquestive Therapeutics reported entry into a material definitive credit agreement with a new lender and simultaneous termination of its previous credit agreement on May 13 2026. The company also recorded first-quarter financial results, created a direct financial obligation, and…
insidermonkey.comCollegium Pharmaceutical Completes Acquisition and Names New Director
Collegium Pharmaceutical Inc. closed an acquisition disclosed in an 8-K filing on May 12 2026 and reported the election of a new board member. The transaction alters the company's asset base and governance while triggering standard SEC financial disclosure obligations in coming w…
marketwatch.comAurinia Pharmaceuticals Completes Acquisition of Assets
Aurinia Pharmaceuticals Inc. reported the completion of an acquisition of assets in an 8-K filing with the SEC on May 11 2026. The transaction triggers updated financial disclosures and sets contractual milestones for the company and the seller.
aircargoweek.comAssertio Holdings Reports Departure of Chief Commercial Officer
Assertio Holdings disclosed the departure of its chief commercial officer in an 8-K filing. The change triggers standard executive-transition disclosures and requires the company to identify any successor or interim arrangements in follow-on SEC filings.
theblaze.comPfizer Discloses 2026 Financial Results in SEC Filing
Pfizer Inc filed a Form 8-K with the Securities and Exchange Commission on May 5, 2026, reporting results of operations and financial condition along with related financial statements and exhibits. The disclosure provides investors with official details on the company's operation…
today.comRecall Issued for Limited Batch of Xanax XR Pills Nationwide
A small number of Xanax XR pills have been recalled across the United States. The recall affects only specific batches of the anti-anxiety medication sold under the brand name Xanax XR.
medpagetoday.comFDA Announces Panel Meeting on Allowing Compounding Pharmacies to Produce Certain Peptides
The U.S. Food and Drug Administration announced a panel meeting to discuss permitting compounding pharmacies to manufacture seven specific peptides. The meeting is scheduled for July 23 and 24. This follows the agency's 2023 decision to remove 19 peptides from an approved list fo…
France 24Revolution Medicines' Daraxonrasib Trial Reports 13.2-Month Median Survival in Pancreatic Cancer Patients
Revolution Medicines announced results from a late-stage trial of its experimental oral drug daraxonrasib for pancreatic cancer patients. Patients receiving daraxonrasib had a median overall survival of 13.2 months, compared to 6.7 months for those on standard intravenous cytotox…
Substrate placeholder — needs reviewCosmo Pharma Finishes Year-Long Trial Monitoring Hair Growth in Male Pattern Baldness Treatment
Cosmo Pharma completed a year-long study on its male hair loss treatment. The study demonstrated sustained hair growth in participants throughout the one-year period. @Reuters reported the findings from the research.
Substrate placeholder — needs reviewGSK Presents Early-Stage Data on Experimental Cancer Drug and Plans Five Phase 3 Trials
GSK presented data from an early-stage clinical trial of an experimental cancer drug over the weekend. The company stated that the results support advancing the drug to five Phase 3 trials this year. This development follows initial testing to evaluate the drug's safety and preli…
Substrate placeholder — needs reviewRevolution Medicines' Daraxonrasib Succeeds in Phase 3 Trial for Pancreatic Cancer
Revolution Medicines announced that its targeted pill daraxonrasib met primary and secondary endpoints in a Phase 3 trial for metastatic pancreatic cancer patients. The drug extended median survival to 13.2 months compared to 6.7 months with chemotherapy and reduced the risk of d…
Substrate placeholder — needs reviewRevolution Medicines' Daraxonrasib Succeeds in Phase 3 Pancreatic Cancer Trial
Revolution Medicines announced that its drug daraxonrasib met primary and secondary endpoints in a Phase 3 trial for pancreatic cancer patients whose disease had progressed on prior treatment. The trial showed a median overall survival of 13.2 months for daraxonrasib compared to…
Substrate placeholder — needs reviewSpyre Therapeutics' SPY001 Drug Meets Primary Goal in Phase 2 Ulcerative Colitis Trial
Spyre Therapeutics announced positive results from the first batch of data in its Phase 2 SKYLINE study for SPY001, an experimental treatment for ulcerative colitis. The drug achieved a 9.2-point decrease in disease activity and induced remission in about 40% of participants afte…
Substrate placeholder — needs reviewGSK Plans Five Simultaneous Late-Stage Trials for Potential Blockbuster Cancer Drug
GSK Plc announced plans for five concurrent phase 3 trials of a targeted cancer therapy following promising early data. The initiative aims to advance the drug toward potential blockbuster status. The new CEO is leading efforts to revitalize the company's approach to innovation.
thehindu.comNew Oral GLP-1 Drugs Offer Maintenance Option for Weight Loss After Injections
Eli Lilly and Novo Nordisk have introduced oral versions of their GLP-1 receptor agonist drugs for weight management. These pills provide an alternative to weekly injections, with clinical data showing they help maintain weight loss. Side effects and costs remain similar to the i…
Substrate placeholder — needs reviewNewsletter Roundup: Pharmaceutical Updates and Campus Policy Investigations
STAT News distributed its Pharmalittle newsletter featuring pharmaceutical industry developments from the Pharmalot campus. Fox News issued its Campus Radicals newsletter covering an Antifa-linked group's activities and a school investigation into transgender policies. These upda…
Usa TodayFDA Approves Oral GLP-1 Weight-Loss Drugs Foundayo and Wegovy as Alternatives to Injections
The U.S. Food and Drug Administration approved oral versions of GLP-1 weight-loss drugs from Eli Lilly and Novo Nordisk in late 2025 and early 2026. These pills, branded as Foundayo and Wegovy, offer daily dosing without refrigeration and at lower costs compared to weekly injecti…
BtoBEvents / Wikimedia (CC0)PhRMA CEO John Ubl to Depart Amid Biotech Industry Developments
John Ubl, chief executive of the Pharmaceutical Research and Manufacturers of America, plans to exit his role. The announcement comes as the traditional biotech venture capital model faces challenges. These updates are part of broader news in the biotech sector reported by STAT N…
Substrate placeholder — needs reviewUniCredit Shifts Equity Capital Markets Approach, CVC Seeks Partners for Recordati, Seven & i Delays US IPO
UniCredit has adjusted its strategy in equity capital markets. CVC Capital Partners is looking for partners in a potential deal for Recordati. Seven & i Holdings has postponed the initial public offering of its US unit.
Substrate placeholder — needs reviewCVC Capital Partners Seeks Co-Investors for €10.9 Billion Recordati Takeover Bid
Private equity firm CVC Capital Partners is seeking co-investors to fund its proposed €10.9 billion ($12.7 billion) acquisition of Italian pharmaceutical company Recordati. The effort follows CVC's initial offer for the drugmaker, which specializes in treatments for rare diseases…
citizen.co.zaGLP-1 Weight Loss Drugs Drive Potential $13 Billion Boost in Apparel Retail Spending
Millions of individuals using GLP-1 drugs for weight loss are increasing their purchases of new clothing from retailers. Equity research firm Bernstein estimates this trend could generate up to $13 billion in annual spending for the apparel sector. The development highlights a gr…
Substrate placeholder — needs reviewEli Lilly Launches Oral GLP-1 Medication Orforglipron for Weight Loss in the United States
Eli Lilly and Company has introduced Foundayo, the brand name for orforglipron, an oral GLP-1 receptor agonist approved for weight management. The pill offers a non-injectable alternative to existing treatments in the growing obesity drug market. Availability begins in the US, ta…
Substrate placeholder — needs reviewAvalyn Pharma Files for US Initial Public Offering to Develop Inhaled Respiratory Treatments
Avalyn Pharma, a biopharmaceutical company focused on inhaled therapies for respiratory diseases, has filed for an initial public offering in the United States. The filing aims to raise capital for advancing its pipeline of treatments targeting conditions such as pulmonary fibros…
Oak Ridge National Laboratory / Wikimedia (CC BY 2.0)Insmed Halts Development of TPX-201 for Hidradenitis Suppurativa After Phase 2 Trial Failure
Insmed Incorporated announced the discontinuation of its topical drug TPX-201 for hidradenitis suppurativa following negative results from a Phase 2 clinical trial. The trial did not meet its primary endpoint of achieving Hidradenitis Suppurativa Clinical Response at Week 12. The…